1. Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy
- Author
-
Yutong Zou, Yuancheng Zhao, Rui Zhang, Fang Liu, Huan Xu, Jiali Wang, Honghong Ren, Yucheng Wu, Lijun Zhao, Chai Zhonglin, Lin Li, Mark E. Cooper, Yiting Wang, Chunmei Qin, Nan Wei Tong, Tingli Wang, and Junlin Zhang
- Subjects
serum uric acid ,medicine.medical_specialty ,type 2 diabetes mellitus ,Endocrinology, Diabetes and Metabolism ,Disease ,urologic and male genital diseases ,Gastroenterology ,Diseases of the endocrine glands. Clinical endocrinology ,Diabetic nephropathy ,Endocrinology ,Internal medicine ,Biopsy ,Internal Medicine ,medicine ,renal outcome ,Survival analysis ,medicine.diagnostic_test ,Proportional hazards model ,business.industry ,Research ,diabetic nephropathy ,Hazard ratio ,Type 2 Diabetes Mellitus ,RC648-665 ,medicine.disease ,Quartile ,business - Abstract
Objective To investigate the relationship between serum uric acid (SUA) level and renal outcome in patients with type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN). Methods A total of 393 Chinese patients with T2DM and biopsy-proven DN and followed at least 1 year were enrolled in this study. Patients were stratified by the quartiles of baseline level of SUA: Q1 group: 286.02 ± 46.66 μmol/L (n = 98); Q2 group: 358.23 ± 14.03 μmol/L (n = 99); Q3 group: 405.50 ± 14.59 μmol/L (n = 98) and Q4 group: 499.14 ± 56.97μmol/L (n = 98). Renal outcome was defined by progression to end-stage renal disease (ESRD). Kaplan–Meier survival analysis and Cox proportional hazards model were used to analyze the association between SUA quartiles and the renal outcomes. Results During the median 3-year follow-up period, there were 173 ESRD outcome events (44.02%). No significant difference between SUA level and the risk of progression of DN (P = 0.747) was shown in the Kaplan–Meier survival analysis. In multivariable-adjusted model, hazard ratios for developing ESRD were 1.364 (0.621–2.992; P = 0.439), 1.518 (0.768–3.002; P = 0.230) and 1.411 (0.706–2.821; P = 0.330) for the Q2, Q3 and Q4, respectively, in comparison with the Q1 (P = 0.652). Conclusions No significant association between SUA level and renal outcome of ESRD in Chinese patients with T2DM and DN was found in our study. Besides, the role of uric acid-lowering therapy in delaying DN progression and improving ESRD outcome had not yet been proven. Further study was needed to clarify the renal benefit of the uric acid-lowering therapy in the treatment of DN.
- Published
- 2021
- Full Text
- View/download PDF